Study Explores Effect of Hybrid Closed-Loop Therapy on Diabetic Complications
By Elana Gotkine HealthDay Reporter
FRIDAY, Feb. 28, 2025 -- For young people with type 1 diabetes, hybrid closed-loop insulin delivery does not affect the rate of severe hypoglycemia and is associated with an increased risk for diabetic ketoacidosis, but it is also associated with a lower risk for hypoglycemic coma, according to a study published online in the February issue of The Lancet Diabetes & Endocrinology.
Beate Karges, M.D., from RWTH Aachen University in Germany, and colleagues conducted a population-based cohort study involving young people with type 1 diabetes participating in the Diabetes Prospective Follow-up initiative. Participants were aged 2 to 20 years, with a diabetes duration of more than one year. The analysis included 13,922 young people: 7,088 used closed-loop therapy and 6,834 used open-loop therapy.
The researchers found that the rate of ketoacidosis was higher for those using closed- versus open-loop therapy (1.74 versus 0.96 per 100 patient-years; incidence rate ratio, 1.81), while there was no significant between-group difference in the rate of severe hypoglycemia. The rate of hypoglycemic coma was significantly lower for individuals using closed- versus open-loop therapy (0.62 versus 0.91 per 100 patient-years; incidence rate ratio, 0.68). Compared with those in the open-loop therapy group, patients in the closed-loop therapy group had a lower hemoglobin A1c level, higher percentage of time in target glucose range of 3.9 to 10.0 mmol/L, and less glycemic variability. For those with an HbA1c of 8.5 percent or higher, the rate of ketoacidosis was particularly high in the closed-loop versus open-loop therapy group.
"The findings of this study could have clinical implications for the care of young people with type 1 diabetes," the authors write.
Several authors disclosed ties to the pharmaceutical and medical technology industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Endocrine Society, July 12-15
The annual meeting of the Endocrine Society (ENDO 2025) was held from July 12 to 15 in San Francisco, attracting more than 7,000 participants, including clinicians, academicians...
American Diabetes Association, June 20-23
The annual meeting of the American Diabetes Association was held this year from June 20 to 23 in Chicago, drawing more than 15,000 participants, including clinicians...
Risk for Death, MACE Increased for Patients With Adult-Onset Type 1 Diabetes
FRIDAY, May 16, 2025 -- Adult-onset type 1 diabetes (T1D) is associated with an increased risk for death and major adverse cardiovascular events (MACE), according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.